Welcome to uWAMIT – The University of Washington’s Center for Molecular Imaging and Therapy.
The (u)ltrasound-based (W)ashington (M)olecular (I)maging and (T)herapy center, or uWAMIT, focuses on the discovery, development, translation, and commercialization of molecular imaging and therapy technologies.
At uWAMIT we believe molecular imaging and therapy will shape the future of medicine enabling personalized diagnosis and treatment of diseases. Because molecules themselves are too small to be imaged directly, specific site-targeted probes are employed as beacons to identify areas of interest. These site-targeted probes enhance a selected region that otherwise would be impossible to distinguish from surrounding tissue. Attaching specific pharmaceutical agents to these site-targeted probes enables localized delivery of treatments to the diseased site in the body.
uWAMIT’s development of molecular imaging and therapy is focused on:
1) Use of Ultrasound in Molecular Imaging and Therapy: Ultrasound’s availability, low cost, and real-time operation enables molecular diagnosis to transform the way medicine is conducted around the world.
2) Early Stage Cancer Detection: Use of cancer specific molecular probes that attach to cancerous regions in the body enabling early stage screening and diagnosis of Prostate, Ovarian, Colon and many other cancers.
3) Targeted Drug Delivery for Cancer Treatment: Use of specific molecular probes attached to pharmaceutical agents such as chemotherapeutics to deliver targeted treatment only to the effected cancerous region.
4) Targeted Gene Therapy: Use of ultrasound mediated gene transfer for the treatment of genetic diseases such as hemophilia, diabetes, muscular dystrophy, and cystic fibrosis.
5) Development and Manufacturing of Site-Targeted Molecular Probes: uWAMIT develops manufacturing processes to efficiently produce and characterize contrast agents, nanoparticles, and various other molecular bio-markers.
Please visit our Research page to learn more about our current research projects.